FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study)

Abstract

We planned a multicenter randomized phase III study to evaluate the efficacy of appropriate dose of bevacizumab (5 or 10 mg/kg) with FOLFIRI in patients with advanced/metastatic colorectal cancer who have failed prior bevacizumab plus oxaliplatin-based therapy. The primary endpoint is progression-free survival. The secondary endpoints are the toxicity, response rate, time to treatment failure, overall survival, overall survival from the start of the first-line treatment and second progression-free survival (time duration from the initiation of the first-line treatment until progression after the protocol treatment). A total of 370 patients were considered to be appropriate for this trial.

DOI: 10.1093/jjco/hyr180

Extracted Key Phrases

Statistics

0100200201220132014201520162017
Citations per Year

71 Citations

Semantic Scholar estimates that this publication has 71 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@inproceedings{Mishima2012FOLFIRIPB, title={FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study)}, author={Hideyuki Mishima and Koji Oba and Junichi Sakamoto and Kei Muro and Takayuki Yoshino and Ichinosuke Hyodo and Yoshihiko Maehara}, booktitle={Japanese journal of clinical oncology}, year={2012} }